Already a Subscriber?

Not a Subscriber?

Ophthalmology - “Mynosys and the Science of Market Penetration: A Case Study from Navigant Consulting”

By Michelle D. Edwards and Mary Stuart, Senior Writer/Market Analyst

Mynosys developed a device that automates the only manual part of cataract surgery, the world’s most common surgery, thereby increasing its precision and improving outcomes. But that wasn’t going to be enough to gain market adoption of a premium product in a bundled procedure already offering slim margins for physicians. Working with the consulting firm Navigant, the company implemented two successful strategies for market penetration.

Surgical Robotics - “J&J Bets Big in Robotic Surgery”

By David Cassak, Co-Editor-in-Chief

J&J’s recent blockbuster deal for Auris is really just the latest in a series of moves the company has made recently in positioning the diversified medtech giant in the exploding field of robotically-enabled surgery. From Verb, its joint venture with Verily, to Orthotaxy to, now, Auris, J&J is developing and advancing what the company calls “a comprehensive digital surgery experience.”

Regenerative Medicine - “Applying Regenerative Medicine, Stavros Thomopoulos Tackles the Challenges of Tendon-to-Bone Healing”

By Wendy Diller, Senior Writer/Market Analyst

Durable tendon-to-bone healing is among the biggest challenges in orthopedics, with implications for long-term success of common surgical procedures like shoulder repairs and ACLs. Leading orthopedics bioengineer Stavros Thomopoulos of Columbia University is at the forefront of research on solutions based on a better understanding of the processes that prevent tendon-to-bone healing and the regenerative technologies most likely to help. Part three of a three-part series.

M&A - “Boston Scientific Aims High in Oncology”

By Mark Ratner, Contributing Writer

Although 2018 sales of Boston Scientific’s current interventional oncology products were barely worth a mention in recent financial disclosures, it hopes, with the acquisition of BTG, to become a significant player in oncology to help sustain the growth investors are now expecting.

Precision Oncology - “Why Cancer Precision Medicine is Relevant to the Device Industry”

By Wendy Diller, Senior Writer/Market Analyst

Precision medicine is being applied more broadly in healthcare, fueled partly by scientific advances (read: targeted drug therapies and advances in genomic analysis) and growing evidence of proven clinical benefits. Experiences in more established specialties such as lung and other cancers show how precision medicine has implications for the medtech world, particularly in the area of tissue biopsies and interventional treatment procedures.

Intensive Care - “Reactive Robotics: In the ICU, Robots Enable the Human Touch”

By Mary Stuart, Senior Writer/Market Analyst

Very early mobilization therapies have the potential to avoid a host of co-morbidities that come with prolonged bedrest in the ICU, but there is a shortage of personnel for administering these manual and very physical therapies. Reactive Robotics believes its VEMO therapy, a robotic system that enables verticalization and movement of patients in their beds, can provide this therapy, allowing caregivers to focus on the more human aspects of patient care.

Neurology - “Zeto: Sensing Improvement in Neurological Data Processing”

By Colin Miller, Contributing Writer

EEG is the gold standard for observing and characterizing neural activity, but patients are subject to lengthy and uncomfortable preparation for scans, and interpretation is subjective to the physician who reads it. Zeto has introduced a novel design designed for patient comfort and simple setup, which uses “active” dry electrodes capable of picking up cerebral activity with high digital resolution and less noise.

Not a Subscriber?

Already a Subscriber?

Want a Sample Article?